文献速递肺结节与肺癌

埃克替尼对比化疗辅助治疗II-IIIA期EGFR突变非小细胞肺癌(EVIDENCE):随机开放标签3期试验

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2021-07-21

该多中心随机开放标签3期试验在中國29家医院纳入322例完全切除的II-IIIA期EGFR突变NSCLC患者,比较埃克替尼与化疗的辅助治疗效果。总生存数据尚未成熟。

要点

  • 埃克替尼辅助治疗显著延长II-IIIA期EGFR突变NSCLC完全切除后的无病生存期。
  • 埃克替尼治疗相关严重不良事件发生率低于化疗(1% vs 14%)。

核心结论

  • 在完全切除的II-IIIA期EGFR突变NSCLC患者中,与化疗相比,埃克替尼显著改善无病生存期且耐受性更好。

研究设计与样本

  • 多中心、随机、开放标签、3期试验,在中国29家医院进行。
  • eligible患者为18-70岁、组织学确诊II-IIIA期NSCLC、随机前8周内完全切除、未接受过治疗、确认EGFR外显子19或21激活突变。
  • 322例患者随机1:1接受埃克替尼(n=161)或化疗(n=161);全分析集包括埃克替尼组151例和化疗组132例。
  • 埃克替尼口服125 mg每日三次,持续2年;化疗为4个21天周期(腺癌或鳞癌:长春瑞滨25 mg/m2第1和8天+顺铂75 mg/m2第1天;非鳞癌:培美曲塞500 mg/m2+顺铂75 mg/m2第1天每3周)。
  • 主要终点为全分析集的无病生存期;次要终点为全分析集的总生存期和所有接受研究药物参与者的安全性。

主要发现

  • 埃克替尼组40/151例(26%)和化疗组58/132例(44%)出现疾病复发或死亡。

关键数值与推荐

  • 治疗相关严重不良事件发生率埃克替尼组1% vs 化疗组14%。

临床怎么用

  • 对于完全切除的II-IIIA期EGFR突变NSCLC患者,可考虑埃克替尼辅助治疗以改善无病生存。
  • 埃克替尼辅助治疗的耐受性优于化疗,治疗相关严重不良事件较少。
  • 总生存获益尚未成熟,需长期随访确认。

局限性

  • 本报告为预设中期分析,总生存数据未成熟。
  • 开放标签设计可能影响部分主观终点的评估。
  • 全分析集排除部分随机患者,可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Icotinib has provided survival benefits for patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to compare icotinib with chemotherapy in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection. Here, we report the results from the preplanned interim analysis of the study. METHODS: In this multicentre, randomised, open-label, phase 3 trial done at 29 hospitals in China, eligible patients were aged 18-70 years, had histopathogically confirmed stage II-IIIA NSCLC, had complete resection up to 8 weeks before random assignment, were treatment-naive, and had confirmed activation mutation in exon 19 or exon 21 of the EGFR gene. Participants were randomly assigned (1:1) with an interactive web-based response system to receive either oral icotinib 125 mg thrice daily for 2 years or four 21-day cycles of intravenous chemotherapy (vinorelbine 25 mg/m2 on days 1 and 8 of each cycle plus cisplatin 75 mg/m2 on day 1 of each cycle for adenocarcinoma or squamous carcinoma; or pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 on day 1 every 3 weeks for non-squamous carcinoma). The primary endpoint was disease-free survival assessed in the full analysis set. Secondary endpoints were overall survival assessed in the full analysis set and safety assessed in all participants who received study drug. This trial is registered with ClinicalTrials.gov, NCT02448797. FINDINGS: Between June 8, 2015, and August 2, 2019, 322 patients were randomly assigned to icotinib (n=161) or chemotherapy (n=161); the full analysis set included 151 patients in the icotinib group and 132 in the chemotherapy group. Median follow-up in the full analysis set was 24·9 months (IQR 16·6-36·4). 40 (26%) of 151 patients in the icotinib group and 58 (44%) of 132 patients in the chemotherapy group had disease relapse or death. Median disease-free survival was 47·0 months (95% CI 36·4-not reached) in the icotinib group and 22·1 months (16·8-30·4) in the chemotherapy group (stratified hazard ratio [HR] 0·36 [95% CI 0·24-0·55]; p<0·0001). 3-year disease-free survival was 63·9% (95% CI 51·8-73·7) in the icotinib group and 32·5% (21·3-44·2) in the chemotherapy group. Overall survival data are immature with 14 (9%) deaths in the icotinib group and 14 (11%) deaths in the chemotherapy. The HR for overall survival was 0·91 (95% CI 0·42-1·94) in the full analysis set. Treatment-related serious adverse events occurred in two (1%) of 156 patients in the icotinib group and 19 (14%) of 139 patients in the chemotherapy group. No interstitial pneumonia or treatment-related death was observed in either group. INTERPRETATION: Our results suggest that compared with chemotherapy, icotinib significantly improves disease-free survival and has a better tolerability profile in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection. FUNDING: Betta Pharmaceuticals TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021. PMID: 34280355. doi:10.1016/S2213-2600(21)00134-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。